Robert Courtney, MD
Retina Specialist · Lafayette, CONPI 1760649024
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.5%), ownership interests and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by US Retina LLC at 36.6% of the total.
Across 122 payments — averaging $57.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$3K
- AbbVie$963
- Regeneron Healthcare Solutions, Inc.$818
- Genentech, Inc.$544
- Genentech USA, Inc.$471
- Apellis Pharmaceuticals, Inc.$294
- plus $1K from 14 others
What the payments were for
- Grants$831%
- Food & beverage$3,61151%
- Education$75111%
- Ownership interest$2,57237%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 4 | $2,572 |
| AbbVie(2 entities) | 9 | $963 |
| Regeneron Healthcare Solutions, Inc. | 31 | $818 |
| Genentech, Inc. | 3 | $544 |
| Genentech USA, Inc. | 23 | $471 |
| Apellis Pharmaceuticals, Inc. | 7 | $294 |
| Novartis | 7 | $227 |
| Astellas Pharma US Inc | 8 | $170 |
| Astellas Pharma Global Development | 1 | $164 |
| Ocular Therapeutix, Inc. | 2 | $134 |
| Alimera Sciences, Inc. | 6 | $123 |
| Biogen | 5 | $100 |
| Eyepoint US, Inc. | 2 | $97 |
| Coherus Oncology, Inc. | 4 | $94 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $75 |
| Neurotech Pharmaceuticals, Inc. | 2 | $56 |
| Bausch & Lomb Americas Inc. | 2 | $47 |
| Harrow Eye, LLC | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 2 | $32 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,017 in reported general payments places this provider in the 60th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 88 | $3,854 |
| Brimonidine Tartrate | 65 | $1,147 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 69 | $835 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 43 | $628 |
| Ketorolac Tromethamine | 30 | $615 |
| MoxifloxacinMoxifloxacin Hcl | 11 | $463 |
| Latanoprost | 38 | $263 |
| Timolol Maleate | 15 | $80 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Lafayette
- Ashleigh LevisonLafayette$33K
- Murtaza AdamParker$548K
- Alan KimuraDenver$546K
- Brian JoondephDenver$92K
- Talisa ForestAurora$84K
- Sara HaugDurango$59K
- Matthew ManryLongmont$43K
- Mimi LiuEnglewood$23K
- Moss FenbergDurango$20K
- Lynn HassmanAurora$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.